Insulet (PODD) Tops Q3 EPS by 34c; offers guidance

Insulet (NASDAQ: PODD) reported Q3 EPS of $0.74, $0.34 better than the analyst estimate of $0.40. Revenue for the quarter came in at $432.7 million versus the consensus estimate of $414.32 million.

For the year ending December 31, 2023, the Company is raising its expected revenue growth to a range of 26% to 27% (previously 22% to 25%).

For earnings history and earnings-related data on Insulet (PODD) click here.

You May Also Be Interested In

• Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Offic
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Movano (MOVE) Misses Q2 EPS by 195c